Background & Aims Pioglitazone is effective for long-term treatment of patients with nonalcoholic
steatohepatitis (NASH) with prediabetes or type 2 diabetes. However, it is not clear how …

OBJECTIVE The 2019 Standards of Medical Care in Diabetes suggested that patients with
nonalcoholic fatty liver disease (NAFLD) should be evaluated for liver fibrosis. However, the …

Background & Aims Alpha-1 antitrypsin deficiency (AATD) is an uncommonly recognized
cause of liver disease in adults, with descriptions of its natural history limited to case series and …

Fibromax is a diagnostic tool composed of the combination of 4 non-invasive biomarker
panels for the diagnosis of steatosis (SteatoTest), necrosis and inflammation (ActiTest and …

Telaprevir and boceprevir are the first direct‐acting antiviral agents approved for use in
HCV treatment and represent a significant advance in HCV therapy. However, these first‐…

BACKGROUND & AIMS: Liver disease is a significant cause of death among adults with α 1
-antitrypsin (A-AT) deficiency. Age and male sex are reported risk factors for liver disease. In …

Alpha‐1 antitrypsin deficiency (AATD) liver disease is characterized by marked heterogeneity
in presentation and progression, despite a common underlying gene mutation, strongly …

Background Cyclosporine has antiviral activity in vitro against hepatitis C (HCV). We performed
a pilot study to prospectively determine the antiviral effect of cyclosporine during therapy …

Alpha-1 antitrypsin (AAT) deficiency is a genetic condition that increases the risk for liver
disease and chronic obstructive pulmonary disease (COPD). The protein deficiency was first …

Background/Aims Interleukin‐28B (IL‐28B) polymorphism is the strongest pretreatment
predictor of viral clearance in the hepatitis C (HCV) population. Donor and recipient IL‐28B …